Figure 7: DR-18 promotes GVL after haploidentical transplantation.

B6D2F1 recipients were lethally irradiated and transplanted with 5 × 10⁶ BM and 2 × 10⁶ T cells from HULK (IFNγ-YFP x IL-10-GFP x FoxP3-RFP) donors and 1 × 10⁶ BCR-ABL-NUP98hox9 leukemia cells. Recipients were untreated (haploBMT) or administered 50 mg/kg PT-Cy on D+3 and D+4 (PT-Cy) with or without decoy resistant IL-18 (PT-Cy + DR-18; 8μg twice weekly from D+7 to week 5) or CD137 agonist antibody (PT-Cy + αCD137; 100 μg twice weekly from D+7 to week 5). (A) Experimental design. (B) Number of GFP⁺ leukemia cells in blood, leukemic death and overall median survival. (C-J) Mice with <5% leukemia cells in BM were sacrificed at 21 days after transplantation and BM was analyzed (n = 4–5; 1 experiment). (C) Total numbers of CD8⁺ T, CD4⁺ T, and NK cells. (D) Percentage of IFNγ-producing CD8⁺ and CD4⁺ T cells. (E) Co-expression of DNAM-1 and TIGIT and (F) MFI on CD8⁺ T cells. (G) Expression of TIM-3 and TOX on CD8⁺ T cells. (H) Granzyme A and B expression in CD8⁺ T cells. (I) IFNγ and (J) granzyme A and B production in NK cells. One-way ANOVA with Tukey’s multiple comparisons test and Log-rank for survival. Data is mean ± SEM * p<0.05, **p<0.01, ***p<0.001